Bilbao Asset Management
Contributor since: 2018
Latest Articles
A Marijuana Trade: Green Organic Dutchman Could Soon Produce 156,000 Kilograms Of Cannabis
Centrexion IPO: At Phase 3, But Don't Expect The Share Price To Go To The Moon
CNFinance IPO: Loans Given Increased By 123% In 2017
Hoth Therapeutics IPO: Small Company Targeting A Large Market
Carbon Black: Short Sellers Send The Stock Price To Undervalued Levels
Twist IPO: It Seems Undervalued, And Shareholders Are Buying
Cannabis Merger: Shareholders Should Receive More For MPX Bioceutical
Orchard IPO: Product Candidates From GlaxoSmithKline, And Seems Undervalued
Pintec Technology IPO: Growing Revenues At 936% Year-Over-Year
Valtech IPO: Almost 13% Y/Y Revenue Growth
Buffett's Stock Pick: StoneCo IPO Shows 74% Y/Y Revenue Growth
Studio City IPO: Undervalued, But Extremely Risky
Niu Technologies IPO: 116.83% Revenue Growth And Undervalued
vTv Therapeutics: Data Expected At The End Of 2018
Alzheon IPO: Wait Until 2019 If You Are Buying Shares
Guardant IPO: 97.4% Y/Y Revenue Growth And Seems Undervalued
Elastic IPO: Amazing Business, But It Seems Overvalued
Urovant IPO: Phase 3 Clinical Data To Be Released In 2019
Ra Medical Systems IPO: Expensive At 30x Sales
Arvinas IPO: 40% Is Cash, But Research Is At An Early Stage
Eventbrite IPO: It Seems A Buy At 4.5x Forward Sales
SurveyMonkey IPO: With Salesforce Buying, Share Price Could Increase
Zekelman Industries IPO: Risky, But Not Expensive
Navios Maritime Containers IPO: Not Expensive, But Quite Risky
Elanco Animal Health IPO: Undervalued, But Risky
111, Inc. IPO: World's Largest Virtual Pharmacy Network Is Expensive
AGM Group: Impressive Business Growth, But Seems Overvalued
YayYo IPO: Car Sharing At Very Expensive 109x Forward Sales
GE's Bet On Neuronetics: Sell It At 8.32x Forward Sales
ParkerVision Seems A Short: Massive Stock Dilution And Trading At 103x Sales
BlackLine: Strong Quarter With 32% Revenue Growth
Bloom Energy: 95% Stock Return